238 related articles for article (PubMed ID: 25828157)
1. Microstructure and compressive mechanical properties of cortical bone in children with osteogenesis imperfecta treated with bisphosphonates compared with healthy children.
Imbert L; Aurégan JC; Pernelle K; Hoc T
J Mech Behav Biomed Mater; 2015 Jun; 46():261-70. PubMed ID: 25828157
[TBL] [Abstract][Full Text] [Related]
2. Increased intra-cortical porosity reduces bone stiffness and strength in pediatric patients with osteogenesis imperfecta.
Vardakastani V; Saletti D; Skalli W; Marry P; Allain JM; Adam C
Bone; 2014 Dec; 69():61-7. PubMed ID: 25238898
[TBL] [Abstract][Full Text] [Related]
3. Macroscopic anisotropic bone material properties in children with severe osteogenesis imperfecta.
Albert C; Jameson J; Tarima S; Smith P; Harris G
J Biomech; 2017 Nov; 64():103-111. PubMed ID: 28988680
[TBL] [Abstract][Full Text] [Related]
4. Mechanical and mineral properties of osteogenesis imperfecta human bones at the tissue level.
Imbert L; Aurégan JC; Pernelle K; Hoc T
Bone; 2014 Aug; 65():18-24. PubMed ID: 24803077
[TBL] [Abstract][Full Text] [Related]
5. Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation.
Blouin S; Fratzl-Zelman N; Glorieux FH; Roschger P; Klaushofer K; Marini JC; Rauch F
J Bone Miner Res; 2017 Sep; 32(9):1884-1892. PubMed ID: 28548288
[TBL] [Abstract][Full Text] [Related]
6. Reduced diaphyseal strength associated with high intracortical vascular porosity within long bones of children with osteogenesis imperfecta.
Albert C; Jameson J; Smith P; Harris G
Bone; 2014 Sep; 66():121-30. PubMed ID: 24928496
[TBL] [Abstract][Full Text] [Related]
7. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
Weber M; Roschger P; Fratzl-Zelman N; Schöberl T; Rauch F; Glorieux FH; Fratzl P; Klaushofer K
Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
[TBL] [Abstract][Full Text] [Related]
8. Altered lacunar and vascular porosity in osteogenesis imperfecta mouse bone as revealed by synchrotron tomography contributes to bone fragility.
Carriero A; Doube M; Vogt M; Busse B; Zustin J; Levchuk A; Schneider P; Müller R; Shefelbine SJ
Bone; 2014 Apr; 61():116-24. PubMed ID: 24373921
[TBL] [Abstract][Full Text] [Related]
9. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
Shapiro JR; McCarthy EF; Rossiter K; Ernest K; Gelman R; Fedarko N; Santiago HT; Bober M
Calcif Tissue Int; 2003 Feb; 72(2):103-12. PubMed ID: 12457260
[TBL] [Abstract][Full Text] [Related]
10. Unique micro- and nano-scale mineralization pattern of human osteogenesis imperfecta type VI bone.
Fratzl-Zelman N; Schmidt I; Roschger P; Roschger A; Glorieux FH; Klaushofer K; Wagermaier W; Rauch F; Fratzl P
Bone; 2015 Apr; 73():233-41. PubMed ID: 25554599
[TBL] [Abstract][Full Text] [Related]
11. The functional muscle-bone unit in patients with osteogenesis imperfecta type I.
Veilleux LN; Pouliot-Laforte A; Lemay M; Cheung MS; Glorieux FH; Rauch F
Bone; 2015 Oct; 79():52-7. PubMed ID: 26004918
[TBL] [Abstract][Full Text] [Related]
12. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
13. Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment.
Bi X; Grafe I; Ding H; Flores R; Munivez E; Jiang MM; Dawson B; Lee B; Ambrose CG
J Bone Miner Res; 2017 Feb; 32(2):347-359. PubMed ID: 27649409
[TBL] [Abstract][Full Text] [Related]
14. Osteogenesis Imperfecta: Skeletal Outcomes After Bisphosphonate Discontinuation at Final Height.
Robinson ME; Trejo P; Palomo T; Glorieux FH; Rauch F
J Bone Miner Res; 2019 Dec; 34(12):2198-2204. PubMed ID: 31356699
[TBL] [Abstract][Full Text] [Related]
15. Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.
Brunetti G; Papadia F; Tummolo A; Fischetto R; Nicastro F; Piacente L; Ventura A; Mori G; Oranger A; Gigante I; Colucci S; Ciccarelli M; Grano M; Cavallo L; Delvecchio M; Faienza MF
Osteoporos Int; 2016 Jul; 27(7):2355-2365. PubMed ID: 26856585
[TBL] [Abstract][Full Text] [Related]
16. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.
Rauch F; Plotkin H; Zeitlin L; Glorieux FH
J Bone Miner Res; 2003 Apr; 18(4):610-4. PubMed ID: 12674321
[TBL] [Abstract][Full Text] [Related]
17. Alterations of bone material properties in growing Ifitm5/BRIL p.S42 knock-in mice, a new model for atypical type VI osteogenesis imperfecta.
Hedjazi G; Guterman-Ram G; Blouin S; Schemenz V; Wagermaier W; Fratzl P; Hartmann MA; Zwerina J; Fratzl-Zelman N; Marini JC
Bone; 2022 Sep; 162():116451. PubMed ID: 35654352
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.
Jacobsen CM; Schwartz MA; Roberts HJ; Lim KE; Spevak L; Boskey AL; Zurakowski D; Robling AG; Warman ML
Bone; 2016 Sep; 90():127-32. PubMed ID: 27297606
[TBL] [Abstract][Full Text] [Related]
19. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
[TBL] [Abstract][Full Text] [Related]
20. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.
Sakkers R; Kok D; Engelbert R; van Dongen A; Jansen M; Pruijs H; Verbout A; Schweitzer D; Uiterwaal C
Lancet; 2004 May; 363(9419):1427-31. PubMed ID: 15121405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
